TRAX Stock Explodes Higher As Traders Pile Into Momentum

First Tracks Biotherapeutics Inc. stocks have been trading up by 54.07 percent, driven by highly positive clinical trial news.

Live Update At 17:03:43 EDT: On Thursday, July 09, 2026 First Tracks Biotherapeutics Inc. stock [NASDAQ: TRAX] is trending up by 54.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

First Tracks Biotherapeutics Inc., trading under ticker TRAX, is acting like a classic high-volatility biotech name. On the chart, TRAX has exploded from about $17–$19 in late June to a close near $32 on 2026/07/09. That is a huge percentage move in a short window, and it tells traders this is a momentum vehicle, not a sleepy swing.

Under the hood, TRAX is still firmly in development mode. The latest quarterly report shows net income of about -$50M and negative free cash flow near -$32.6M. Return on equity and return on assets are both deeply negative, which fits a company pouring money into research rather than generating steady profits.

At the same time, TRAX holds roughly $248M in cash and about $286M when you include equivalents and short-term investments. With working capital over $250M and essentially no long-term debt, First Tracks Biotherapeutics Inc. has runway to keep spending. For traders, that combination — big cash, negative earnings, and a thin float — often fuels powerful squeezes and sharp pullbacks. TRAX fits that playbook right now.

Why Traders Are Watching TRAX Price Action

TRAX has turned into a textbook momentum case study on both the daily and intraday charts. In late June, First Tracks Biotherapeutics Inc. chopped between roughly $16 and $20, building a base. Then, starting around 2026/07/02, TRAX began grinding higher, closing at $19.30, then $20.04, and $19.78, with higher highs and higher lows forming a steady uptrend.

The real fireworks hit on 2026/07/09. TRAX opened near $21 and ran as high as $33.70 before settling around $32.40. That’s a massive intraday range and a clear range expansion day — the kind of move that pulls in breakout traders, shorts, and late chasers all at once.

Zooming into the 5‑minute chart, TRAX shows exactly the kind of behavior momentum traders look for. Early in the regular session, the stock pushed from the low $20s into the high $20s by late morning, then reclaimed $30 around midday. After a midday consolidation between about $29.50 and $30.50, TRAX broke again in the afternoon, stepping up into the low $30s and hitting that $33.70 spike into the final hour.

This intraday staircase pattern — push, consolidate, push — often signals aggressive dip-buying and shorts getting squeezed. For active traders, TRAX offers clear levels: prior resistance zones around $30, $31, and $33 now act as reference points. If TRAX holds above those former breakout areas on future sessions, the momentum story stays alive. If it cracks hard back into the low $20s, that will confirm the move was a blow-off top.

Conclusion

TRAX is not a quiet, fundamentally stable compounder. First Tracks Biotherapeutics Inc. is burning tens of millions per quarter, posting negative earnings and heavy research spend. But it also carries a large cash hoard, minimal traditional debt, and a development-stage profile that tends to attract speculative capital. That’s why traders are crowding into TRAX right now — the chart is doing the talking.

The daily move from sub‑$20 levels to the low $30s in a matter of days, capped by a $21-to-$33.70 breakout, makes TRAX a prime watchlist name for pattern traders, especially those who focus on gap-and-go and afternoon breakout setups. The intraday action shows clean levels and strong follow-through, but also the kind of volatility that punishes anyone overstaying a move.

For newer traders watching TRAX, the lesson is simple: respect both the opportunity and the danger. This is a fast stock tied to a company that is still losing money and relying on its balance sheet to keep moving forward. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. As Tim Sykes likes to say, “The market rewards prepared traders who cut losses quickly and never fall in love with a stock.” TRAX is the kind of ticker where that mindset is not optional — it’s survival.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks